![logo](/logos/LCTX.webp)
Lineage Cell Therapeutics, Inc.
AMEX:LCTX
0.97 (USD) • At close November 27, 2023
Overzicht | Financiële gegevens
Bedrijfsnaam | Lineage Cell Therapeutics, Inc. |
Symbool | LCTX |
Munteenheid | USD |
Prijs | 0.95 |
Beurswaarde | 166,237,658 |
Dividendpercentage | 0% |
52-weken bereik | 0.93 - 1.58 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Brian M. Culley M.A., M.B.A. |
Website | https://www.lineagecell.com |
An error occurred while fetching data.
Over Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)